metaEvidence - overview

button bars forest bayes pooled summary circles

benefit
(statisticaly significant)

benefit (nominaly significant, not statitically demonstrated)

not significant

harm statitically significant

harm not significant

low certainty due to bias


			deaths (OS)
mGC or mGEJC - L1 - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 neg/PDL1 positive
versus Standard of Care (SoC)
	nivolumab plus SoC vs. Standard of Care (SoC)	2
mGC or mGEJC - L1 - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 negative
versus Standard of Care (SoC)
	nivolumab plus SoC vs. Standard of Care (SoC)	1
mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive
versus placebo plus SoC
	pembrolizumab alone vs. placebo plus SoC	1
	pembrolizumab plus SoC vs. placebo plus SoC	2
versus Standard of Care (SoC)
	pembrolizumab alone vs. Standard of Care (SoC)	1